Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution 3.0 Unported Licence
Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors
Yue Donga,
Min Liua,
Jian Wangb,
Zhuang Dinga and
Bin Sun*a
aInstitute of BioPharmaceutical Research, Liaocheng University, 1 Hunan Road, Liaocheng 252000, PR China
bKey Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China
First published on 26th July 2024
Abstract
Correction for ‘Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors’ by Yue Dong et al., RSC Adv., 2019, 9, 26302–26314, https://doi.org/10.1039/c9ra03713f.
The authors regret that an incorrect version of Fig. 8 was included in the original article. The correct version of Fig. 8 is presented here.
Fig. 8 (A1–6) Polarizing microscopy results of Candida albicans treated with the positive control drugs (fluconazole and terbinafine) and the target compounds (5, 6 and 8) at the specific concentration of 8 mg mL. (B1–4) TEM results for Candida albicans treated with the target compound (8) at the specific concentration of 8 mg mL−1.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
| This journal is © The Royal Society of Chemistry 2024 |